CTLA4 and melanoma: The success of ipilimumab, which is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody (mAb), in the treatment of advanced melanoma started a new era of immune checkpoint inhibitors (ICIs) in systemic anti-cancer treatment [1].